Investigational New Drugs View Homepage


Ontology type: schema:Periodical     


Journal Info

START YEAR

1983

PUBLISHER

Springer US

LANGUAGE

en

HOMEPAGE

http://link.springer.com/journal/10637

Recent publications latest 20 shown

  • 2019-04-11 Emodin, a natural anthraquinone, suppresses liver cancer in vitro and in vivo by regulating VEGFR2 and miR-34a.
  • 2019-04-06 Safety and clinical activity of the Notch inhibitor, crenigacestat (LY3039478), in an open-label phase I trial expansion cohort of advanced or metastatic adenoid cystic carcinoma.
  • 2019-04 Long-term adverse event: inflammatory orbitopathy induced by pembrolizumab in a patient with metastatic melanoma
  • 2019-04 The marine natural product Scalarin inhibits the receptor for advanced glycation end products (RAGE) and autophagy in the PANC-1 and MIA PaCa-2 pancreatic cancer cell lines
  • 2019-04 Sarcoid-like reaction mimicking disease progression in an ALK-positive lung cancer patient receiving lorlatinib
  • 2019-04 A phase 1 trial of SGN-CD70A in patients with CD70-positive diffuse large B cell lymphoma and mantle cell lymphoma
  • 2019-04 Euphol, a tetracyclic triterpene, from Euphorbia tirucalli induces autophagy and sensitizes temozolomide cytotoxicity on glioblastoma cells
  • 2019-04 A phase I study of the farnesyltransferase inhibitor Tipifarnib in combination with the epidermal growth factor tyrosine kinase inhibitor Erlotinib in patients with advanced solid tumors
  • 2019-04 Inhibition of SHP2 by new compounds induces differential effects on RAS/RAF/ERK and PI3K/AKT pathways in different cancer cell types
  • 2019-03-30 Cellular uptake evaluation of pentagamaboronon-0 (PGB-0) for boron neutron capture therapy (BNCT) against breast cancer cells
  • 2019-03-28 Emodin induced necroptosis in the glioma cell line U251 via the TNF-α/RIP1/RIP3 pathway
  • 2019-03-19 The exosome secretion inhibitor neticonazole suppresses intestinal dysbacteriosis-induced tumorigenesis of colorectal cancer
  • 2019-03-18 A phase I, dose-escalation study of PF-06650808, an anti-Notch3 antibody–drug conjugate, in patients with breast cancer and other advanced solid tumors
  • 2019-03-18 Cytotoxicity of [HuArgI (co)-PEG5000]-induced arginine deprivation to ovarian Cancer cells is autophagy dependent
  • 2019-03-16 Ramucirumab as a second line therapy for advanced HCC: a significant achievement or a wasted opportunity for personalised therapy?
  • 2019-03-07 Increased DKC1 expression in glioma and its significance in tumor cell proliferation, migration and invasion
  • 2019-02-28 Population pharmacokinetic analysis of AR-67, a lactone stable camptothecin analogue, in cancer patients with solid tumors
  • 2019-02-21 Phase I study of TAS-121, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, in patients with non-small-cell lung cancer harboring EGFR mutations
  • 2019-02-11 An orally antitumor chalcone hybrid inhibited HepG2 cells growth and migration as the tubulin binding agent
  • 2019-02-08 LEF1-AS1 contributes to proliferation and invasion through regulating miR-544a/ FOXP1 axis in lung cancer
  • JSON-LD is the canonical representation for SciGraph data.

    TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

    [
      {
        "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
        "about": [
          {
            "id": "http://scigraph.springernature.com/ontologies/product-market-codes/H33160", 
            "inDefinedTermSet": "http://scigraph.springernature.com/ontologies/product-market-codes/", 
            "name": "Oncology", 
            "type": "DefinedTerm"
          }, 
          {
            "id": "http://scigraph.springernature.com/ontologies/product-market-codes/B21007", 
            "inDefinedTermSet": "http://scigraph.springernature.com/ontologies/product-market-codes/", 
            "name": "Pharmacology/Toxicology", 
            "type": "DefinedTerm"
          }
        ], 
        "alternateName": "Novel Anti-Cancer Therapeutics and Therapies", 
        "contentRating": [
          {
            "author": "snip", 
            "ratingValue": "0.909", 
            "type": "Rating"
          }, 
          {
            "author": "sjr", 
            "ratingValue": "1.573", 
            "type": "Rating"
          }, 
          {
            "author": "impact_factor_wos", 
            "dateCreated": "2014", 
            "ratingValue": "2.919", 
            "type": "Rating"
          }, 
          {
            "author": "impact_factor_wos", 
            "dateCreated": "2012", 
            "ratingValue": "3.498", 
            "type": "Rating"
          }, 
          {
            "author": "impact_factor_wos", 
            "dateCreated": "2012", 
            "ratingValue": "3.498", 
            "type": "Rating"
          }, 
          {
            "author": "impact_factor_wos", 
            "dateCreated": "2008", 
            "ratingValue": "3.396", 
            "type": "Rating"
          }, 
          {
            "author": "impact_factor_wos", 
            "dateCreated": "2017", 
            "ratingValue": "3.502", 
            "type": "Rating"
          }, 
          {
            "author": "impact_factor_wos", 
            "dateCreated": "2016", 
            "ratingValue": "3.484", 
            "type": "Rating"
          }, 
          {
            "author": "impact_factor_wos", 
            "dateCreated": "2016", 
            "ratingValue": "3.484", 
            "type": "Rating"
          }, 
          {
            "author": "impact_factor_wos", 
            "dateCreated": "2015", 
            "ratingValue": "3.281", 
            "type": "Rating"
          }, 
          {
            "author": "impact_factor_wos", 
            "dateCreated": "2015", 
            "ratingValue": "3.281", 
            "type": "Rating"
          }, 
          {
            "author": "impact_factor_wos", 
            "dateCreated": "2014", 
            "ratingValue": "2.919", 
            "type": "Rating"
          }, 
          {
            "author": "impact_factor_wos", 
            "dateCreated": "2013", 
            "ratingValue": "2.927", 
            "type": "Rating"
          }, 
          {
            "author": "impact_factor_wos", 
            "dateCreated": "2013", 
            "ratingValue": "2.927", 
            "type": "Rating"
          }, 
          {
            "author": "impact_factor_wos", 
            "dateCreated": "2010", 
            "ratingValue": "3.007", 
            "type": "Rating"
          }, 
          {
            "author": "impact_factor_wos", 
            "dateCreated": "2010", 
            "ratingValue": "3.007", 
            "type": "Rating"
          }, 
          {
            "author": "impact_factor_wos", 
            "dateCreated": "2009", 
            "ratingValue": "3.072", 
            "type": "Rating"
          }, 
          {
            "author": "impact_factor_wos", 
            "dateCreated": "2011", 
            "ratingValue": "3.357", 
            "type": "Rating"
          }, 
          {
            "author": "impact_factor_wos", 
            "dateCreated": "2011", 
            "ratingValue": "3.357", 
            "type": "Rating"
          }, 
          {
            "author": "impact_factor_wos", 
            "dateCreated": "2009", 
            "ratingValue": "3.072", 
            "type": "Rating"
          }, 
          {
            "author": "impact_factor_wos", 
            "dateCreated": "2008", 
            "ratingValue": "3.396", 
            "type": "Rating"
          }
        ], 
        "description": "

    The development of new anticancer agents is one of the most rapidly changing aspects of cancer research. Investigational New Drugs provides a forum for the rapid dissemination of information on new anticancer agents. The papers published are of interest to the medical chemist, toxicologist, pharmacist, pharmacologist, biostatistician and clinical oncologist. Investigational New Drugs provides the fastest possible publication of new discoveries and results for the whole community of scientists developing anticancer agents.

    Each issue contains original articles dealing with anticancer drug development. Other sections are devoted to invited review articles and letters to the editor. The journal also affords the opportunity to publish the proceedings of special workshops and symposia devoted to the development of new anticancer agents. Provided they add to the understanding of the investigational agents, the journal is not adverse to publishing clinical trials with negative results.

    Investigational New Drugs cuts across all the usual lines or subdisciplines, providing a locus for the presentation of relevant investigations and the discussion of critical questions appropriate to the entire field of new anticancer drug development.

    ", "editor": [ { "familyName": "Rowinsky", "givenName": "Eric K.", "type": "Person" } ], "id": "sg:journal.1094201", "inLanguage": [ "en" ], "isAccessibleForFree": false, "issn": [ "0167-6997", "1573-0646" ], "license": "Hybrid (Open Choice)", "name": "Investigational New Drugs", "productId": [ { "name": "scopus_id", "type": "PropertyValue", "value": [ "22477" ] }, { "name": "wos_id", "type": "PropertyValue", "value": [ "0167-6997/INVESTIGATIONAL NEW DRUGS" ] }, { "name": "nlm_unique_id", "type": "PropertyValue", "value": [ "8309330" ] }, { "name": "nsd_ids_id", "type": "PropertyValue", "value": [ "442160" ] }, { "name": "springer_id", "type": "PropertyValue", "value": [ "10637" ] }, { "name": "lccn_id", "type": "PropertyValue", "value": [ "sn 84009586" ] }, { "name": "dimensions_id", "type": "PropertyValue", "value": [ "94201" ] }, { "name": "era_ids_id", "type": "PropertyValue", "value": [ "14781" ] } ], "publisher": { "name": "Springer US", "type": "Organization" }, "publisherImprint": "Springer", "sameAs": [ "https://app.dimensions.ai/discover/publication?and_facet_source_title=jour.1094201" ], "sdDataset": "journals", "sdDatePublished": "2019-03-18T11:05", "sdLicense": "https://scigraph.springernature.com/explorer/license/", "sdPublisher": { "name": "Springer Nature - SN SciGraph project", "type": "Organization" }, "sdSource": "file:///home/ubuntu/piotr/scigraph_export/journals_20190313_sn_only.jsonl", "startYear": "1983", "type": "Periodical", "url": "http://link.springer.com/journal/10637" } ]
     

    Download the RDF metadata as:  json-ld nt turtle xml License info

    HOW TO GET THIS DATA PROGRAMMATICALLY:

    JSON-LD is a popular format for linked data which is fully compatible with JSON.

    curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/journal.1094201'

    N-Triples is a line-based linked data format ideal for batch operations.

    curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/journal.1094201'

    Turtle is a human-readable linked data format.

    curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/journal.1094201'

    RDF/XML is a standard XML format for linked data.

    curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/journal.1094201'


     

    This table displays all metadata directly associated to this object as RDF triples.

    214 TRIPLES      22 PREDICATES      52 URIs      46 LITERALS      32 BLANK NODES

    Subject Predicate Object
    1 sg:journal.1094201 schema:about sg:ontologies/product-market-codes/B21007
    2 sg:ontologies/product-market-codes/H33160
    3 schema:alternateName Novel Anti-Cancer Therapeutics and Therapies
    4 schema:contentRating N07c4043469d0432f8362c9336f158bd6
    5 N11085488292a459ca01133ed40ec210f
    6 N32c516d84eb54f7aa3a35eb6a9963b8f
    7 N335cbd5c49b240c9af6c84717f69242c
    8 N368f41ee819845eeb30cce6b772d764a
    9 N4372844e761c4af1acb88fb3eb28b023
    10 N4ff947738d65424bbddf4bab33387d52
    11 N559af0c65c90453d8ede22483626cc07
    12 N686cc1a26c4d48d6b659a513e25517d0
    13 N76cad94f45d042508c54721ca1d47141
    14 N7e815b84f98640b0898660db1058e264
    15 N8c18635c7527450eb47a27baf7542928
    16 N8ded5f9716eb46cc8494fc1adab3ad27
    17 N905bfc258fb84dc188414875eb073f78
    18 N92353e561ddf481b8b3c89c8de7f0259
    19 N9464de5a1ef64621937a56c9a03d9650
    20 Na3dbd98c8d694c8c8dd503aa066c58ec
    21 Nb435d28264f64a25b6ddfcd118a45909
    22 Nb47b0d894eca47e58b6fe2e93d10d4d0
    23 Nc842ab7c335e4e2da470cfdc1e1b8807
    24 Nf46b36c37a614c54bf07cba3ed1a34e9
    25 schema:description <p>The development of new anticancer agents is one of the most rapidly changing aspects of cancer research. <i>Investigational New Drugs</i> provides a forum for the rapid dissemination of information on new anticancer agents. The papers published are of interest to the medical chemist, toxicologist, pharmacist, pharmacologist, biostatistician and clinical oncologist. <i>Investigational New Drugs</i> provides the fastest possible publication of new discoveries and results for the whole community of scientists developing anticancer agents.<br/><br/>Each issue contains original articles dealing with anticancer drug development. Other sections are devoted to invited review articles and letters to the editor. The journal also affords the opportunity to publish the proceedings of special workshops and symposia devoted to the development of new anticancer agents. Provided they add to the understanding of the investigational agents, the journal is not adverse to publishing clinical trials with negative results.<br/><br/><i>Investigational New Drugs</i> cuts across all the usual lines or subdisciplines, providing a locus for the presentation of relevant investigations and the discussion of critical questions appropriate to the entire field of new anticancer drug development.</p>
    26 schema:editor N8858d631e5e7495aaa0185adf1ec6638
    27 schema:inLanguage en
    28 schema:isAccessibleForFree false
    29 schema:issn 0167-6997
    30 1573-0646
    31 schema:license Hybrid (Open Choice)
    32 schema:name Investigational New Drugs
    33 schema:productId N04b76fc7ef6b4ba9a39ee5b9e5bb987f
    34 N1d66c6be257a49d7af1acc2787a7a09e
    35 N79697a8638234d189d81e277720d0019
    36 Nb1178f70aa174dda91e5c291d888cf65
    37 Nbad7d31ca1144ad6aa283ee31074af89
    38 Nbc2bcebd74204d2d848a44f6938a40b2
    39 Ncda124d7a4634d8c941e45491b7a6579
    40 Nfe0a7599a4804e8ab35d610693fc71c9
    41 schema:publisher N71db7917baea43c08cd85312ff9a3f42
    42 schema:publisherImprint Springer
    43 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_source_title=jour.1094201
    44 schema:sdDatePublished 2019-03-18T11:05
    45 schema:sdLicense https://scigraph.springernature.com/explorer/license/
    46 schema:sdPublisher Nc73247720b404083a11d094ad95f16e5
    47 schema:startYear 1983
    48 schema:url http://link.springer.com/journal/10637
    49 sgo:license sg:explorer/license/
    50 sgo:sdDataset journals
    51 rdf:type schema:Periodical
    52 N04b76fc7ef6b4ba9a39ee5b9e5bb987f schema:name nlm_unique_id
    53 schema:value 8309330
    54 rdf:type schema:PropertyValue
    55 N07c4043469d0432f8362c9336f158bd6 schema:author N61b341b656a14226b72932d76c254f30
    56 schema:dateCreated 2009
    57 schema:ratingValue 3.072
    58 rdf:type schema:Rating
    59 N0829f736c93a4c58a176dc990135fd4b rdf:first impact_factor_wos
    60 rdf:rest rdf:nil
    61 N103d79f88973479abbea816a78a517ed rdf:first impact_factor_wos
    62 rdf:rest rdf:nil
    63 N11085488292a459ca01133ed40ec210f schema:author N973569b3ac424bf9b9539767c9152a7a
    64 schema:dateCreated 2011
    65 schema:ratingValue 3.357
    66 rdf:type schema:Rating
    67 N152c111a298f4196a694ef9d84f15b54 rdf:first impact_factor_wos
    68 rdf:rest rdf:nil
    69 N19ee891407cc4fce8dae5fadd25fc405 rdf:first impact_factor_wos
    70 rdf:rest rdf:nil
    71 N1d66c6be257a49d7af1acc2787a7a09e schema:name era_ids_id
    72 schema:value 14781
    73 rdf:type schema:PropertyValue
    74 N23e68b01e29a49c6bd44d3ce17e11e6e rdf:first impact_factor_wos
    75 rdf:rest rdf:nil
    76 N293636a381bb4017803934a7bc6b070c rdf:first impact_factor_wos
    77 rdf:rest rdf:nil
    78 N32c516d84eb54f7aa3a35eb6a9963b8f schema:author Naa5dcae5d4604012b81b25adf8300a26
    79 schema:dateCreated 2012
    80 schema:ratingValue 3.498
    81 rdf:type schema:Rating
    82 N335cbd5c49b240c9af6c84717f69242c schema:author N19ee891407cc4fce8dae5fadd25fc405
    83 schema:dateCreated 2012
    84 schema:ratingValue 3.498
    85 rdf:type schema:Rating
    86 N347dace2c1b541cbacb0f2a66fe9fa37 rdf:first impact_factor_wos
    87 rdf:rest rdf:nil
    88 N368f41ee819845eeb30cce6b772d764a schema:author Nd18585e153054b46969fa34af6d5ae0d
    89 schema:ratingValue 0.909
    90 rdf:type schema:Rating
    91 N430858d35127435d8fa4f70bca52ef6d rdf:first impact_factor_wos
    92 rdf:rest rdf:nil
    93 N4372844e761c4af1acb88fb3eb28b023 schema:author N23e68b01e29a49c6bd44d3ce17e11e6e
    94 schema:dateCreated 2016
    95 schema:ratingValue 3.484
    96 rdf:type schema:Rating
    97 N4ff947738d65424bbddf4bab33387d52 schema:author N8227ab92af504261b819d53e9daecb8b
    98 schema:dateCreated 2009
    99 schema:ratingValue 3.072
    100 rdf:type schema:Rating
    101 N559af0c65c90453d8ede22483626cc07 schema:author Na25e72688d4047f1ad513ec2cdb6600b
    102 schema:dateCreated 2008
    103 schema:ratingValue 3.396
    104 rdf:type schema:Rating
    105 N61b341b656a14226b72932d76c254f30 rdf:first impact_factor_wos
    106 rdf:rest rdf:nil
    107 N67c4c6e6d4434611b1e9c68a128405b6 rdf:first impact_factor_wos
    108 rdf:rest rdf:nil
    109 N686cc1a26c4d48d6b659a513e25517d0 schema:author N77e9d038866940dcbae53c086032edda
    110 schema:ratingValue 1.573
    111 rdf:type schema:Rating
    112 N6945df3b0e8d4ac98047c689c17edaf3 rdf:first impact_factor_wos
    113 rdf:rest rdf:nil
    114 N71db7917baea43c08cd85312ff9a3f42 schema:name Springer US
    115 rdf:type schema:Organization
    116 N76cad94f45d042508c54721ca1d47141 schema:author N152c111a298f4196a694ef9d84f15b54
    117 schema:dateCreated 2016
    118 schema:ratingValue 3.484
    119 rdf:type schema:Rating
    120 N77e9d038866940dcbae53c086032edda rdf:first sjr
    121 rdf:rest rdf:nil
    122 N79697a8638234d189d81e277720d0019 schema:name scopus_id
    123 schema:value 22477
    124 rdf:type schema:PropertyValue
    125 N7e815b84f98640b0898660db1058e264 schema:author Nf5c6e0a0d82341f7b4d1aa4d555de68e
    126 schema:dateCreated 2011
    127 schema:ratingValue 3.357
    128 rdf:type schema:Rating
    129 N8227ab92af504261b819d53e9daecb8b rdf:first impact_factor_wos
    130 rdf:rest rdf:nil
    131 N830ed6ea49134c7e9b8adaa510911938 rdf:first impact_factor_wos
    132 rdf:rest rdf:nil
    133 N86aa326f823e485c9dd7003c809b6353 rdf:first impact_factor_wos
    134 rdf:rest rdf:nil
    135 N8858d631e5e7495aaa0185adf1ec6638 rdf:first Nb850f53ff82345779a63935090689f2a
    136 rdf:rest rdf:nil
    137 N8c18635c7527450eb47a27baf7542928 schema:author N830ed6ea49134c7e9b8adaa510911938
    138 schema:dateCreated 2014
    139 schema:ratingValue 2.919
    140 rdf:type schema:Rating
    141 N8ded5f9716eb46cc8494fc1adab3ad27 schema:author N67c4c6e6d4434611b1e9c68a128405b6
    142 schema:dateCreated 2010
    143 schema:ratingValue 3.007
    144 rdf:type schema:Rating
    145 N905bfc258fb84dc188414875eb073f78 schema:author Ndda8cb81a7b74c90b4f4ed3e980154f9
    146 schema:dateCreated 2015
    147 schema:ratingValue 3.281
    148 rdf:type schema:Rating
    149 N92353e561ddf481b8b3c89c8de7f0259 schema:author N0829f736c93a4c58a176dc990135fd4b
    150 schema:dateCreated 2010
    151 schema:ratingValue 3.007
    152 rdf:type schema:Rating
    153 N9464de5a1ef64621937a56c9a03d9650 schema:author N103d79f88973479abbea816a78a517ed
    154 schema:dateCreated 2017
    155 schema:ratingValue 3.502
    156 rdf:type schema:Rating
    157 N973569b3ac424bf9b9539767c9152a7a rdf:first impact_factor_wos
    158 rdf:rest rdf:nil
    159 Na25e72688d4047f1ad513ec2cdb6600b rdf:first impact_factor_wos
    160 rdf:rest rdf:nil
    161 Na3dbd98c8d694c8c8dd503aa066c58ec schema:author N6945df3b0e8d4ac98047c689c17edaf3
    162 schema:dateCreated 2015
    163 schema:ratingValue 3.281
    164 rdf:type schema:Rating
    165 Naa5dcae5d4604012b81b25adf8300a26 rdf:first impact_factor_wos
    166 rdf:rest rdf:nil
    167 Nb1178f70aa174dda91e5c291d888cf65 schema:name lccn_id
    168 schema:value sn 84009586
    169 rdf:type schema:PropertyValue
    170 Nb435d28264f64a25b6ddfcd118a45909 schema:author N430858d35127435d8fa4f70bca52ef6d
    171 schema:dateCreated 2013
    172 schema:ratingValue 2.927
    173 rdf:type schema:Rating
    174 Nb47b0d894eca47e58b6fe2e93d10d4d0 schema:author N347dace2c1b541cbacb0f2a66fe9fa37
    175 schema:dateCreated 2014
    176 schema:ratingValue 2.919
    177 rdf:type schema:Rating
    178 Nb850f53ff82345779a63935090689f2a schema:familyName Rowinsky
    179 schema:givenName Eric K.
    180 rdf:type schema:Person
    181 Nbad7d31ca1144ad6aa283ee31074af89 schema:name nsd_ids_id
    182 schema:value 442160
    183 rdf:type schema:PropertyValue
    184 Nbc2bcebd74204d2d848a44f6938a40b2 schema:name wos_id
    185 schema:value 0167-6997/INVESTIGATIONAL NEW DRUGS
    186 rdf:type schema:PropertyValue
    187 Nc73247720b404083a11d094ad95f16e5 schema:name Springer Nature - SN SciGraph project
    188 rdf:type schema:Organization
    189 Nc842ab7c335e4e2da470cfdc1e1b8807 schema:author N86aa326f823e485c9dd7003c809b6353
    190 schema:dateCreated 2013
    191 schema:ratingValue 2.927
    192 rdf:type schema:Rating
    193 Ncda124d7a4634d8c941e45491b7a6579 schema:name dimensions_id
    194 schema:value 94201
    195 rdf:type schema:PropertyValue
    196 Nd18585e153054b46969fa34af6d5ae0d rdf:first snip
    197 rdf:rest rdf:nil
    198 Ndda8cb81a7b74c90b4f4ed3e980154f9 rdf:first impact_factor_wos
    199 rdf:rest rdf:nil
    200 Nf46b36c37a614c54bf07cba3ed1a34e9 schema:author N293636a381bb4017803934a7bc6b070c
    201 schema:dateCreated 2008
    202 schema:ratingValue 3.396
    203 rdf:type schema:Rating
    204 Nf5c6e0a0d82341f7b4d1aa4d555de68e rdf:first impact_factor_wos
    205 rdf:rest rdf:nil
    206 Nfe0a7599a4804e8ab35d610693fc71c9 schema:name springer_id
    207 schema:value 10637
    208 rdf:type schema:PropertyValue
    209 sg:ontologies/product-market-codes/B21007 schema:inDefinedTermSet sg:ontologies/product-market-codes/
    210 schema:name Pharmacology/Toxicology
    211 rdf:type schema:DefinedTerm
    212 sg:ontologies/product-market-codes/H33160 schema:inDefinedTermSet sg:ontologies/product-market-codes/
    213 schema:name Oncology
    214 rdf:type schema:DefinedTerm
     




    Preview window. Press ESC to close (or click here)


    ...